Institutional strategies as a mechanism to rationalize the negative effects of the judicialization of access to medicine in Brazil

Table 8 Analysis of Poisson’s regression of the effects of the deployment of DAMNP and CATS on the prevalence of medicines that are within the SUS formulary, outside the SUS formulary with a therapeutic alternative and without therapeutic alternative available by the SUS

Variables	Medicines within the SUS formulary^c		Medicines outside the SUS formulary with a therapeutic alternative^c		Medicines outside the SUS formulary without a therapeutic alternative^c
Variables	APR^a (95.0% CI)^b	p	APR^a (95.0% CI)^b	p	APR^a (95.0% CI)^b	p
DAMNP^d
Before deployment	1.00		1.00		1.00
After deployment	1.07 (0.93–1.24)	0.307	1.38 (0.80–1.29)	0.867	0.83 (0.63–1.34)	0.183
CATS^e
Before deployment	1.00		1.00		1.00
After deployment	0.81 (0.67–0.98)	0.032	1.38 (1.07–1.78)	0.011	0.97 (0.70–1.34)	0.866

^aAdjusted Prevalence ratio; ^bConfidence interval of 95%; ^cModel adjusted according to the origin of the prescription, DAMNP and CATS. ^dDepartment of Assessment of Non-Standardized Medicines; ^eTechnical Chamber of Health Assessment

ISSN: 1472-6963